June 01, 2020
Handing a win to Amneal Pharmaceuticals and Mylan in a battle with Almirall LLC over a patent covering its acne drug Aczone, the Patent Trial and Appeal Board said the generics makers were able to persuasively show that all the challenged claims were invalid.
June 05, 2019
The Patent Trial and Appeal Board seemed to struggle Wednesday to grasp the argument posed by drugmaker Almirall as it attempted to fend off a bid to invalidate its patent covering the acne drug Aczone, with one judge saying the attorney's responses "raised more questions than answers."
May 13, 2019
The Patent Trial and Appeal Board has agreed to review an Almirall patent covering the acne drug Aczone, finding that generics maker Amneal Pharmaceutical LLC's bid for review was not serial because an earlier related challenge involved a different patent.